Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $270.6 million.

  • Ani Pharmaceuticals' Total Current Liabilities rose 4244.76% to $270.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.6 million, marking a year-over-year increase of 4244.76%. This contributed to the annual value of $193.7 million for FY2024, which is 3313.44% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Total Current Liabilities is $270.6 million, which was up 4244.76% from $236.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Total Current Liabilities high stood at $270.6 million for Q3 2025, and its period low was $79.5 million during Q1 2022.
  • In the last 5 years, Ani Pharmaceuticals' Total Current Liabilities had a median value of $125.8 million in 2023 and averaged $136.8 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Total Current Liabilities tumbled by 390.97% in 2022, and later skyrocketed by 6919.44% in 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Total Current Liabilities (Quarter) stood at $87.5 million in 2021, then rose by 13.6% to $99.4 million in 2022, then skyrocketed by 46.3% to $145.5 million in 2023, then surged by 33.13% to $193.7 million in 2024, then soared by 39.69% to $270.6 million in 2025.
  • Its Total Current Liabilities stands at $270.6 million for Q3 2025, versus $236.8 million for Q2 2025 and $201.8 million for Q1 2025.